NCT03100500 - A Long-term Safety Study of QMF149 in Japanese Participants With Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 25, 2017

Primary Completion Date

July 19, 2018

Study Completion Date

February 12, 2019

Conditions

Asthma

Interventions

DRUG

QMF149

QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler

Trial Locations (15)

Novartis Investigative Site, Nagoya

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Chitose

Novartis Investigative Site, Kitahiroshima

Novartis Investigative Site, Sapporo

Novartis Investigative Site, Sapporo

Novartis Investigative Site, Takamatsu

Novartis Investigative Site, Yokohama

Novartis Investigative Site, Yokohama

Novartis Investigative Site, Yokosuka

Novartis Investigative Site, Chino

Novartis Investigative Site, Higashiosaka

Novartis Investigative Site, Chuo Ku

Novartis Investigative Site, Chuo-ku

Novartis Investigative Site, Toshima-ku